Mode
Text Size
Log in / Sign up
N/A Completed N=202

Solitaire FR Thrombectomy for Acute Revascularisation

Stroke, Acute
Source: ClinicalTrials.gov NCT01327989 ↗
Enrolled (actual)
202
Serious AEs
29.2%
Results posted
Jan 2017
Primary outcomePrimary: Arterial Recanalization of the Occluded Target Vessel Measured by Thrombolysis in Cerebral Infarction (TICI) Score Equal or Superior to 2b Following the Use of the Study Device. — 84.2 percentage of particpants

Summary

The objective of this study was to obtain prospective clinical data on the safety and efficacy of the Solitaire™ FR device for patients diagnosed with acute ischemic stroke.

Outcome Measures

OutcomeResultp-value
PRIMARY
Arterial Recanalization of the Occluded Target Vessel Measured by Thrombolysis in Cerebral Infarction (TICI) Score Equal or Superior to 2b Following the Use of the Study Device.
84.2 —
PRIMARY
Incidence of Device-related and Procedure-related Serious Adverse Events (SAEs).
7.4 —
SECONDARY
Time to Achieve Revascularization - Groin Stick to Initial Angiogram and Final Solitaire™ FR Angiogram
29 —
SECONDARY
Time to Achieve Revascularization - After First Ipsilateral Angiogram to Final Solitaire™ FR Angiogram
37.2 —
SECONDARY
Good Neurological Condition
88.2 —
SECONDARY
Rate of Morbidity
8.4 —
SECONDARY
Rate of Mortality
6.9 —
SECONDARY
Incidence of Symptomatic Intracranial Hemorrhage
1.5 —
SECONDARY
Immediate Flow Reperfusion
11.6 —

Eligibility Criteria

Inclusion Criteria

  • Subject or subject's legally authorized representative has signed and dated an Informed Consent Form
  • Age ≥ 18 and 30 or coma
  • Uncontrolled hypertension defined as systolic blood pressure > 185 or diastolic blood pressure > 110 that cannot be controlled except with continuous parenteral antihypertensive medication
  • Use of warfarin anticoagulation with International Normalised Ratio (INR) > 3.0
  • Platelet count < 30,000
  • Glucose < 400 mg/dL
  • Previous stroke within 30 days
  • Time of symptom onset unknown
  • Seizure at the onset of stroke
  • Myocardial infarction or infection (sepsis or endocarditis)
  • Arterial tortuosity that would prevent the device from reaching the target vessel
  • Known hypersensitivity to nickel-titanium

Imaging Exclusion Criteria:

  • Angiographic evidence of carotid dissection, complete cervical carotid occlusions, or vasculitis
  • Stenosis proximal to thrombus site that may preclude safe recovery of the device
  • Brain computed tomography (CT) with signs of hemorrhage, arteriovenous venous malformations, or aneurysm
  • Early ischemic changes greater than 1/3 of the middle cerebral artery (MCA) territory or according to brain computed tomography (CT) Alberta Stroke Program Early CT (ASPECT) score ≤ 6 or according to magnetic resonance diffusion weighted imaging (MR DWI) ASPECT score <5
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01327989). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search